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Abstract: Nucleobase-containing isoxazolidines spiro-bonded to an indane core have been synthesized
in very good yields by regio- and diastereoselective 1,3-dipolar cycloaddition starting from
indanyl nitrones and N-vinylnucleobases by using environmentally benign microwave technology.
The contemporary presence of various structural groups that are individually active scaffolds of
different typology of drugs, has directed us to speculate that these compounds may act as inhibitors
of MDM2–p53 interaction. Therefore, both computational calculations and antiproliferative screening
against A549 human lung adenocarcinoma cells and human SH-SY5Y neuroblastoma cells were
carried out to support this hypothesis.
Keywords: spirooxindoles; isoxazolidines; MDM2–p53 inhibition; indane derivatives
1. Introduction
Spirocyclic compounds exhibit important bioactivity principally as antimicrobial [1,2],
anticancer [3,4] and anti-inflammatory [5] agents. Their therapeutic properties appear to be due
to the tetrahedral nature of the spiro carbon that makes the two linked rings more or less perpendicular
to each other [6]. In fact, the asymmetric properties of substrates due to chiral spiro center seem to be
an important factor affecting biological activities. In particular, spirooxindoles are characterized by
a variety of rings spiro-bonded to the C3 of the oxindole core with a variable degree of substitution,
which is a scaffold present in many natural products and pharmacologically relevant drugs. [7–10]
Recently, the spirocyclic oxindoles have particularly emerged for their antiviral and anticancer
activity [11–13]. Some representative examples of natural products or pharmaceutical drugs having a
spirooxindole scaffold are illustrated in Figure 1.
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Figure 1. Structure of some representative active spirooxindole derivatives. 
In particular, among the various examples, spirooxindole pyrrolidines with a long carbon chain 
or imidazole/thiazolidine ring have emerged for their anticancer properties against A549 human 
lung adenocarcinoma cell line [14]. Moreover, NITD609 [15] and MI-888 [16] are currently in 
preclinical evaluation as inhibitors of malaria and some human cancer cell lines, respectively. More 
specifically, MI-888 seems to be a potent inhibitor of MDM2–p53 interaction, capable of achieving 
complete regression of two types of human cancers through oral administration, such as SJSA-1 
osteosarcoma and RS4;11 acute lymphoblastic leukaemia tumour xenograft models. In fact, it is now 
widely documented that the protein p53 is a tumour suppressor and its activity consists principally 
in preventing tumour formation, in repair of damaged cells or apoptosis to eliminate irreparable 
cells. However, in several cancers, p53 is effectively inhibited by MDM2 oncoprotein, which is 
generally responsible for regulation of p53 production. [17–22] Therefore, the disruption of the 
MDM2–p53 interaction is recently recognized as the promising strategy for anticancer drug design. 
[23–29] 
Inspired by those results, a number of methods to synthesize oxindole derivatives were realized 
during the last years [30]. The 1,3-dipolar cycloaddition between an oxindole nitrone and an 
unsaturated substrate can be considered the common procedure for the preparation of spirooxindole 
structures or spiroisoxazolidines spiro-bonded to an oxindole scaffold, [31,32] although other 
synthetic strategies are employed including oxidative rearrangement, [33] Heck reaction, [34] 
intramolecular Mannich reaction, [35] ring expansion [36].  
Our group, with wide expertise of Mw-assisted reactions such as 1,3-dipolar cycloadditions 
[37–41], has recently synthesized a series of isatinyl/indanyl nitrones (INs) by a solvent-free 
condensation of alkyl- or arylhydroxylamines hydrochlorides with isatin and indanone using a 
microwave irradiation technique [42]. This methodology can be considered a versatile procedure to 
synthesize nitrones in high yields and a short reaction time, reducing the formation of by-products. 
These substrates have demonstrated high reactivity in successive 1,3-dipolar cycloadditions with 
N-vinylnucleobases to produce spiro-isoxazolidines with oxindole-like core and nucleobase. 
Herein, we describe the synthesis of some diastereomerically pure nucleobase-containing 
spiro-(indane isoxazolidine) derivatives as potential anti-cancer substrates, supported by a 
computational study about a possible inhibition of MDM2–p53 interaction and by their 
antiproliferative evaluation against A549 human lung carcinoma cells and human SH-SY5Y 
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evaluation against A549 human lung carcinoma cells and human SH-SY5Y neuroblastoma cells. In fact,
to our knowledge, there are no spiro-compounds active against A549 and SH-SY5Y cells as inhibitors of
MDM2–p53 interactions, with structural characteristics as our substrates, which are distinguished by
the simultaneous presence of a spiro-carbon, an isoxazolidine portion spiro-bonded to C1 of an indane
ring and a nucleobase, in attempt to significantly increase their inhibitory and antiproliferative activities.
Moreover, one of the investigations that we desire to highlight is that, apart from the isoxazolidine and
nucleobase portion, the indane ring might be an alternative candidate as key moiety, instead of oxindole
core of active spiro-substrates. On the other hand, substituted 1-indanones or indan-1,3-diones have
proven to be potent cytotoxic agents effective against a wide range of diseases. [43,44] Inter alia,
a number of derivatives were active against growth of solid tumors e.g., colon, lung bronchogenic and
osteosarcoma for which few drugs are actually available [45].
2. Results and Discussion
2.1. Chemistry
The spiro (indane-isoxazolidine) derivatives 5a–d were prepared by MW-assisted 1,3-dipolar
cycloaddition reaction between N-vinylnucleobases 4a–d [46] and indanyl nitrone 3, which was
synthesized from 1-indanone 1 and N-methyl hydroxylamine hydrochloride 2 using our previously
reported procedure [42] (Scheme 1).
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contributions to link them to the characteristics of p53 antimetabolites. 
 
c e e 1. Synthetic route to cycloadducts 5a–d. Reagents and conditio s: nitrone (2 equiv.),
-vinylnucleobase (1 equiv.), 750 .
The N-vinyl nucleobases were synthesized by a convenient and one-pot procedure of nucleobase
vinylation developed by our group, avoiding the tedious and multi-step synthetic procedures previously
used [46]. The choice of using nucleobases as one of the bio-active scaffold of our compounds was
oriented towards the possibility to improve the interactions with the active site of the enzymes involved
in this work. With respect to the use of simple aromatic rings as a phenyl group, the nucleobase cycles
can form further interactions, such as hydrogen bonds with their amino or carbonyl groups, in addition
to pi–pi interactions of aromatics systems. In the literature, nucleobases such as antimetabolites of p53
are known, in particular, 5-F-Ura and purine derivatives [47–49]. However, scope of this work was not
to synthesize nucleobase derivatives as antimetabolites of p53, but only improve substrate interactions
with enzymes through their presence on the synthesized molecule backbone, as previously explicated.
On the other hand, during the computational studies [see subsequent section], we have not noticed
any of their particular contributions to link them to the characteristics of p53 antimetabolites.
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The synthetic procedure consists of the co-grinding of ketonitrone and N-vinylnucleobase in a
mortar, followed by transfer of the mixture in an appropriate vessel. Then, after further mixing of
the solids in a vortex without use of solvents, the solid mixture was placed in a microwave oven for
the indicated time. Based on our experience, the grinding phase is important for the reaction trend.
On the other hand, in the literature, it is evident that solid-state chemical reactions among particles can
take place if the latter are small enough to have adequate Surface-to-Volume ratios. In this situation,
the reaction can be carried out in short times and with quantitative formation of products, by the
(interfacial) dynamical processes normally taking place in the solid-state, which are further accelerated
by microwave irradiation. [50–52].
The reaction conditions and results are reported in Table 1.
Table 1. Reaction conditions and results of solvent-free synthesis of cycloadducts 5a–d.
Entry a Time (min) Product Yield (%) Exo/endo Ratio
1 40 5a 77 75:25
2 40 5b 76 78:22
3 45 5c 89 77:23
4 45 5d 86 75:25
a MW = 750 W; T = 125 ◦C.
The optimized reaction conditions were obtained after various attempts, varying power of MW,
temperature and ratio nitrone/nucleobase. All compounds were isolated in high yields and very
short reaction times if compared with those obtained by classical cycloaddition conditions (toluene,
110 ◦C, 3 days; yield 20–30%). Cycloaddition reactions showed a total regioselectivity and moderate
diasteroselectivity, furnishing the 5-substituted regioisomer, as confirmed by 1H-NMR and 13C-NMR
and a prevalent amount of exo-adduct (Table 1). Configuration of the obtained products 5a–d was
confirmed by NOESY NMR experiments, after purification by flash-chromatography and HPLC.
Moreover, the results obtained in terms of the yield and stereoselectivity of the reaction do not seem to
be affected by the pyrimidine or purine nature of the nucleobase.
Because no officially approved biochemical mechanism of inhibition is known for various cancer
lines, as a first approach, we performed computational studies on our substrates 5a–d to focus
mainly on their behaviour as inhibitors of the MDM2–p53 interaction and to study their possible
anti-proliferative action.
2.2. Computational Studies
As explained in the introduction, and demonstrated in many recent works, these type of
spiro-derivatives are able to disrupt the interaction between MDM2 and p53, which is the origin of their
anti-proliferative action [53,54]. Therefore, we performed computational studies on our substrates 5a–d
to focus mainly on their behaviour as disruptors of MDM2–p53 complex and to predict their activity.
MDM2–p53 interaction has been widely explored and has been fully described. p53 binds through
its subdomain TAD1 (part of the N-terminal transactivation domain, TAD), involving residues 17–29,
a hydrophobic cleft in the N-terminal of MDM2 (aa 25–109). [55,56] Three key residues in p53 are
involved in stabilising the interaction: Phe19, Trp23 and Leu26. Although TAD is an intrinsically
disordered domain, TAD1 folds to an alpha-helix when it binds to MDM2, fitting perfectly on the
cleft [57].
Previous docking studies with different compounds capable to inhibit the MDM2–p53 interaction
showed that those compounds are able to mimic the key p53-residues when binding to MDM2 [58,59].
However, very few authors have addressed this system with molecular dynamic simulations, and
only the interaction MDM2-ligand was considered [60,61]. Here, we are considering also p53 in order
to simulate the whole biological system. We have performed molecular docking calculations with all
the synthetized products against MDM2, using Glide and PDB 1YCR as MDM2–p53 structure, deleting
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the p53 moiety. Five derivatives (exo-5a, exo-5b, exo-5c, endo-5c and exo-5d) and the corresponding
enantiomers were evaluated.
In all cases, low binding energies were obtained, very close among most of the ligands (Table S3).
Those poses of minimum energy place the ligand where Phe19 and Trp23 bind to MDM2 (Figure S1A).
Remarkably, exo-(3R,5R)-5a is the only ligand with a pose placing the indane moiety overlapping
Trp23 when superimposing both structures (Figure S1B).
Unfortunately, these small energy differences are not enough for justifying the biological activity
for 5a–d derivatives, due to the complexity and dynamics of the real system, so p53 must be considered
in the interaction, as well as the flexibility of both proteins.
Two type of systems were simulated with molecular dynamics, spiro-isoxazolidines docked to
MDM2 as well as 5a–5d bounded to MDM2 in the presence of p53 (Figure S2). For simulating the
tertiary complex, two starting structures were considered. For the first one, ligands were docked
to the p53–MDM2 complex. For the second starting structure, we firstly manually moved the p53
fragment from the MDM2 hydrophobic cleft, to a distance of 8 Å, and then ligands were docked into
the space between p53 and MDM2. MDs were performed with Amber 16 along at least 500 ns for each
simulation. Molecular dynamics containing exclusively MDM2 and spiro-derivatives did not show
any variation along the simulations, keeping the ligand in the p53 key residues interaction zone, and
no significant changes were observed in the protein structure.
Analogously, tertiary systems starting from the complex MDM2–p53 remained stable along the
simulations. Ligand surrounds p53 for 50 ns, not being able to disrupt the interaction between the two
proteins. After 200 ns, all interaction with MDM2 is lost.
Finally, MD simulations were carried out over the structures containing docked ligands in the
hydrophobic cleft of MDM2 in presence of p53. As reference, we also simulated the same system without
a ligand. In this reference simulation, TAD1 subdomain is able to bind MDM2 in the hydrophobic
groove, folding to a helix in 300 ns of the simulation, remaining completely stable for 200 ns more
(Figure S3).
However, the presence of any ligand in the MDM2 cleft prevents p53 to bind as if there was no
ligand, and is not able to expel completely the spiro-isoxazolidine. p53 only displaces it, and they both
must share the hydrophobic groove, and in most of the simulations, TAD1 is able to fold back to a helix
reaching a stable stationary situation.
Several situations are reached, depending on the spiro-compound: p53 is placed in the same
position as the reference simulation, but its residues do not have the same intermolecular interactions
(Figure 2A); p53 helix can be shifted with respect to the reference structure (Figure 2B); p53 helix twists
laterally, partially losing its structure (Figure 2C).
The only simulation where TAD1 is not able to fold back and remains completely unfolded is
when exo-3R,5R-5a is present, as shown in Figure 3. This disordered structure is stable for more than
500 ns of simulation.
To our knowledge, there has never been comprehensively studied this system with molecular
dynamic simulations so far, and our study suggests a correlation between the antiproliferative activity
of a compound and the incapacity of p53 to fold back in presence of it. This correlation might be deeply
studied and is beyond the aim of this exploratory work.
Intrigued by the results obtained with computational calculations and, in particular, with MD
simulations, we considered it appropriate to investigate, in a preliminary way, the antiproliferative
activity of our substrates against two cancer cell lines, theA549 human lung adenocarcinoma cells and
human SH-SY5Y neuroblastoma cells. As already mentioned previously, these cancer cell lines were
selected for the well-known pharmacological activity by spiro-oxindole derivatives, but not studied
for spiro-indane substrates.
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2.3. Antiproliferative Activity
As already mentioned above, different natural spirooxindoles like Spirotryprostatins A and B
(Figure 1) showed relevant anticancer activities. Particularly, spirooxindole-pyrrolidines (Figure 1)
revealed prominent cell inhibition against the A549 lung human adenocarcinoma cancer cell line
at different concentrations (100, 50 and 25 µg/mL), exhibiting a best biological performance in
spirooxindole-pyrrolidine derivatives alkylated on the N-oxindole ring with a long chain (i.e., hexyl)
than the unsubstituted substrates, probably due to the increased lipophilicity [14].
In this regard, all synthetized compounds 5a–d were assayed for in vitro cell growth control (%)
against the A549 human lung cancer cell line using the most abundant diastereomeric form obtained
for each compound (exo-5a, exo-5b, exo-5c, exo-5d). Only for compound spiro (indane-isoxazolidine),
N-Fluoro uracile 5c, the endo-diastereomeric isomer was examined, hypothesizing that the compound
5c an increased biological performance due to a probable bioisosteric effect of fluorine substituent, as
detected for many generally active substrates [62,63]. Testing the two products exo-5c and endo-5c,
results for the cell growth percentage were comparable for both compounds. For this reason, we leaned
towards the comparison only of exo-derivatives because of their major abundance.
All compounds were checked for cell growth control at different concentrations (µM range),
using SRB assay. In Figure 4, the cell growth control (%) in relation to [substrate] is reported for all
compounds. The exact values along with standard deviation at the concentrations of 25, 50, 100, 200,
250 µM are reported in Table S1 of Supplementary Materials.
All substrates showed activity against the A549 cell line; however, some of the synthesized
compounds exhibited a more evident inhibition performance. In fact, compound pyrimidine
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derivatives with C-5 substitution such as N-thymine derivative (exo-5a) and N-(5-F-Uracil) derivative
(exo-5c) showed increased potencies than the C-5 unsubstituted analogue N-Uracil (exo-5b). The
purine nucleobase present on the N-adenine derivative exo-5d does not confer any improvement of
antiproliferative capacity of substrate, which on the contrary, showed a slighter decrease of activity
than the others.
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3. Materials and Methods
3.1. General
Commercial starting materials were used without further purification. Reactions were monitored
by TLC using silica plates 60-F264, commercially available from Merck (Milano, Italy). 1H and 13C-NMR
spectra and two dimensional NMR spectra were recorded at 400 and 500 MHz and 100 and 125.7 MHz,
respectively, in CDCl3 and DMSO-d6 using tetramethylsilane (TMS) as internal standard (Bruker Avance
500 MHz with a 5 mm TBO probe, Rheinstetten, Germany). Chemical shifts are given in parts per
million and coupling constants in Hertz. The purity and the stereochemistry were established by NMR
spectra (1H-NMR and NOESY experiments). Mass spectra were performed using a Thermo Scientific
Q-ExactiveTM (Rodano, MI, Italy) mass spectrometer. Analysis was operated using electrospray with
positive and negative polaritiy, at 140,000 resolving power, IT 500 ms, and ACG target = 3 × 106,
maximum injection time 200 ms by full scan analysis. Source conditions were: spray voltage 1.0 KV,
capillary temperature: 250 ◦C; S-Lens RF Level: 50. The instrument was calibrated by Thermo
calibration solutions prior to the beginning the analysis. The final substrates were further purified
before biological assays with a semipreparative HPLC Waters 515 pump and injector, employing a
Novapack silica column (19 × 30 mm, particle size 6 um) eluting with a isocratic mixture of hexane and
isopropyl alcohol 95:5 and with a Waters dual wavelength detector 2487. MW-assisted reactions were
performed in Synthos 3000 instrument from Anton Paar, equipped with a 4 × 24 MG5 rotor and an
IR probe as external control of the temperature. 0.3–3 mL glass vials sealed with a dedicated PEEK
screw-cup together with a reliable PTFE seal were used for all reactions.
For the synthesis of N-methyl-C-indanyl nitrone 3 see reference [42].
3.2. General Procedure for Synthesis of 5a–d
The nitrone (2 equiv.) and opportune N-nucleobase (1 equiv.) were grinded in a mortar, placed in
apposite vessel and mixed in a vortex. The mixture was transferred to a microwave oven and was
irradiated at 750 W, fixing Tmax at 125 ◦C. After the appropriate time the crude oil was purified by
flash chromatography with CHCl3/MeOH 9.75:0.25 v/v.
Exo-5′-Thyminyl-2′-methyl-spiro-[indane-3,3′-isoaxazolidine]. Exo-5a White solid, 77% yield.
1H-NMR (400 MHz, CDCl3): δ 1.76–1.90 (m, 1H, CH2), 1.94 (d, J = 1.17 Hz, 3H, CH3), 2.39 (s, 3H, CH3),
2.51–2.67 (m, 2H, CH2), 2.80–2.98 (m, 3H, CH2), 6.21 (dd, J = 5.61 Hz, 7.36 Hz, 1H, CH), 7.13–7.29 (m,
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4H, Ar), 7.79 (s, 1H, 6-CHThy), 9.39 (sb, 1H, NHThy).13C-NMR (100 MHz, CDCl3): δ 12.85, 29.30, 30.23,
36.12, 51.69, 78.00, 82.29, 111.19, 123.64, 125.21, 126.99, 129.09, 135.93, 139.82, 144.40, 150.71, 164.21.
ESI(+)-MS: m/z [M + H] calcd. for C17H20N3O3 314.1499, found: 314.1497.
Exo-5′-Uracil-2′-methyl-spiro-[indane-3,3′-isoaxazolidine]. Exo-5b White solid, 76% yield.
1H-NMR (400 MHz, CDCl3): δ 1.72–1.91 (m, 1H, CH2), 2.39 (s, 3H, CH3), 2.53–2.66 (m, 2H, CH2),
2.80–2.94 (m, 2H, CH2), 2.94–3.02 (m, 1H, CH2), 5.78 (d, J = 8.08 Hz, 1H, 5-CHUra), 6.19 (dd, J = 5.41 Hz,
7.31 Hz, 1H, CH), 7.14–7.30 (m, 4H, Ar), 8.03 (d, J = 8.08 Hz, 1H, 6-CHUra), 9.54 (sb, 1H, NHUra).13C-NMR
(100 MHz, CDCl3): δ 29.44, 35.99, 51.94, 78.07, 82.68, 102.66, 123.69, 125.20, 127.05, 129.17, 139.59, 140.38,
144.34, 150.67, 163.71. ESI(+)-MS: m/z [M + H] calcd. for C16H18N3O3 300.1343, found: 300.1337.
Exo-5′-(5-F-Uracil)-2′-methyl-spiro-[indane-3,3′-isoaxazolidine]. Exo-5c White solid, 89% yield.
1H-NMR (400 MHz, CDCl3): δ 1.78–1.90 (m, 1H, CH2), 2.40 (s, 3H, CH3), 2.52–2.64 (m, 2H, CH2),
2.80–2.94 (m, 2H, CH2), 2.95-3.04 (m, 1H, CH2), 6.17 (m, 1H, CH), 7.15–7.27 (m, 4H, Ar), 8.10 (d,
J = 6.10 Hz, 1H, 6-CHUra), 9.80 (sb, 1H, NHUra).13C-NMR (100 MHz, CDCl3): δ 29.40, 30.18, 35.99, 51.92,
77.98, 82.93, 123.61, 124.63, 125.22, 127.10, 129.20, 139.67, 142.02, 144.32, 149.27, 157.16. ESI(+)-MS: m/z
[M + H] calcd. for C16H17N3O3F 318.1248, found: 318.1240.
Endo-5′-(5-F-Uracil)-2′-methyl-spiro-[indane-3,3′-isoaxazolidine]. Endo-5c White solid, 89% yield.
1H-NMR (400 MHz, CDCl3): δ 2.12–2.22 (m, 1H, CH2), 2.24 (s, 3H, CH3), 2.29–2.44 (m, 1H, CH2), 2.55
(dd, J = 4.43 Hz, 14.02 Hz, 1H, CH2), 2.79–3.00 (m, 2H, CH2), 3.18 (dd, J = 7.75 Hz, 14.02 Hz, 1H,
CH2), 6.26 (ddd, J = 1.37 Hz, 4.34 Hz, 7.75 Hz, 1H, CH), 7.16–7.28 (m, 4H, Ar), 8.05 (d, J = 6.17 Hz, 1H,
6-CHUra), 8.57 (sb, 1H, NHUra).13C-NMR (100 MHz, CDCl3): δ 29.72, 33.19, 37.61, 51.62, 77.89, 83.06,
124.71, 125.06, 126.91, 128.85, 139.41, 140.69, 141.75, 144.07, 148.75, 156.73. ESI(+)-MS: m/z [M + H]
calcd. for C16H17N3O3F 318.1248, found: 318.1241.
Exo-5′-Adenyl-2′-methyl-spiro-[indane-3,3′-isoaxazolidine]. Exo-5d White solid, 86% yield.
1H-NMR (500 MHz, DMSO-d6): δ 1.82–2.02 (m, 1H, CH2), 2,45 (s, 3H, CH3), 2.64–2.81 (m, 1H, CH2),
2.82-3.03 (m, 2H, CH2), 3.04-3.19 (m, 1H, CH2), 6.44 (dd, J = 4.69 Hz, 7.72 Hz, 1H, CH), 7.88 (sb, 2H,
NH2), 7.16–7.37 (m, 4H, Ar), 8.28 (s, 1H, CHAde), 8.51 (s, 1H, CHAde).13C-NMR (125 MHz, CDCl3):
δ 33.78, 34.14, 41.87, 81.42, 82.03, 84.23, 123.11, 129.30, 131.04, 132.70, 133.10, 143.16, 144.92, 148.83,
153.98, 157.08, 160.43. ESI(+)-MS: m/z [M + H] calcd. for C17H19N6O 323.1615, found: 323.1623.
3.3. Computational Study
3.3.1. Protein–LIGAND Docking Calculations
Conformational sampling of ligands 5a–d and flexible docking with MDM2 were carried out
using the Glide protocol in the Schrodinger modelling suite. The crystal structure of MDM2 in
complex with a p53 (PDB entry 1YCR) was used as starting point for the receptor. Three different
protein structures were considered, the first without p53, where p53 moiety was manually deleted, the
second where the MDM2–p53 is conserved unaltered, and the third structure where p53 is manually
moved 8 Å far from the groove. Then, the protein was prepared for docking calculations (hydrogen
atoms added, water removed, hydrogen bonds optimized) using the Protein Preparation Wizard tool
within the Maestro interface. For the grid calculations, a cubic box of 20 Å sides was centred on the
hydrophobic cleft of MDM2. A constrained minimization of the receptor was carried out (OPLS3 force
field, extended cutoffs of 8 Å for van der Waals interactions, 20 Å for electrostatic, and 4 Å for H-bonds,
minimization with a limit of 5000 iterations and a convergence criterium of 0.01). Flexible docking in
extra precision mode (XP) with sampling of ring conformations and nitrogen inversions was carried
out. The energetically most favourable solution from the docking calculations was further minimized.
The docking calculations were carried out with all four enantiomers of each of the five compounds.
3.3.2. Molecular Dynamic Simulations
Protein and ligand structures were separately processed for Amber 16. Proteins were GAFF
forcefield were used for ligands, while FF14SB was employed or proteins. Complexes were set in a
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explicit water TIP3P cubic box of 65 Å side, and charges were compensated. The system was minimized
and heated to 300 K. MD simulations were performed in the isothermal-isobaric ensemble (NPT) at
300 K and 1 bar, under the Periodic Boundary Conditions, using the Langevin thermostat, Berendsen
barostat, non-bonded interaction cutoff set to 10 Å, SHAKE approximation for hydrogen atoms with
a time step of 2 fs. The trajectory was recorded at 10 ps intervals for at least 500 ns. Analysis of the
trajectories was carried out using tools of AMBER and VMD [64].
3.4. Biological Evaluation
3.4.1. Cell Culture
A549 cells were purchased from ATCC and were maintained at 37 ◦C and in a 5% CO2
environment in complete media constituting basal medium Roswell Park Memorial Institute
(RPMI)-1640 supplemented with 10% fetal bovine serum (FBS), 1% penicillin streptomycin and
1% L-glutamine. Briefly, cells in the log phase of growth were harvested and seeded at a density of
1.25 × 105 cells in 96-well plates and cultured till 80% confluency for 24 h at 37 ◦C, 5% CO2. The media
was then replaced with 200 µL of different serially diluted compounds in complete media (with a final
concentration of 0.2% DMSO) to obtain a concentration range of 250–25 µM (n = 3) with 10% dimethyl
sulfoxide (DMSO) serving as a positive control and 0.2% DMSO in complete media serving as negative
control. The plates were further incubated for 48 h. The human SH-SY5Y neuroblastoma cell line, used
for compound Exo-5a, was purchased from ATCC, the Global Bioresource Center, and maintained in
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich Ltd.) supplemented with 5 mg mL−1
penicillin/streptomycin, 10 mM l-glutamine, and 10% (v/v) fetal bovine serum (FBS). Cells were kept in
an incubator at 37 ◦C with a 5% CO2 atmosphere.
3.4.2. Sulforhodamine B assay
The human lung adenocarcinoma cell line A549 (passage number 16–18) was used to study the
in vitro cell growth control (%) assay of the spyrocyclic compounds (exo-5a, exo-5b, exo-5c, endo-5c,
exo-5d) at different concentration (250 µM, 200 µM, 100 µM, 50 µM, 25 µM) and hence validate its
antiproliferative activity. The neuroblastoma cell line SH-SY5Y was used only to test the in vitro cell
growth control (%) assay of spirocyclic compound exo-5a at different concentration (250 µM, 200 µM,
100 µM, 50 µM, 25 µM). After two passages, cells were plated at a density of 2 × 104 per well in a
96-well microplate for the SRB assay. For the Sulforhodamine B (SRB) assay at the end of the incubation
period, cell fixation was carried out by addition of 50 µL of 40% trichloroacetic acid to each well
supernatant for 1 h at 4 ◦C. The plates were then washed with deionized water four times and were
allowed to air-dry at 25 ◦C overnight. Cell staining was carried out by addition of 100 µL of 0.057% of
SRB solution and left at room temperature for 1 h. The plates were washed with 1% acetic acid solution
to remove the unstained SRB reagent four times and allowed to air-dry. 200 µL of 10 mM Tris base
(pH 10.5) was added to solubilize the protein bound SRB dye and optical density (OD) was measured
by spectroscopy (SpectraMAX Plus 384, Molecular Devices, Berkshire, UK) at 510 nm after shaking the
plates mechanically for 5 min. The plate-by-plate examination of the test wells relative to control wells
was employed to determine percent growth, and the ratio of the average absorbance in the test well to
the average absorbance in the control wells × 100 was determined.
3.4.3. Statistical Analysis
The results are expressed by mean ± S.E.M. from at least three independent experiments.
For statistical comparisons, quantitative data were analysed by one-way analysis of variance (ANOVA)
followed by Tukey-test according to the statistical program SigmaStat1 (Jandel Scientific, Chicago, IL,
USA). A p-value less than 0.05 was regarded as significant.
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4. Conclusions
In conclusion, we have synthesized regio- and diastereomerically pure nucleobase-containing
spiro (indane-isoxazolidine) derivatives by MW-assisted 1,3 dipolar cycloaddition between indanyl
nitrones and N-vinylnucleobases in high yields and very short reaction times with respect to classical
cycloaddition conditions. We carried out computational calculations such as docking and molecular
dynamics to study the hypothetical inhibition of MDM2–p53 interaction by our substrates. These
studies highlighted particular comportments, prevalently of the molecule exo-5a, that revealed to be
the most active in the biological tests carried out against A549 human lung adenocarcinoma cells and
SH-SY5Y neuroblastoma cells. We are aware that these studies are preliminary and that, in future,
specific cell lines to confirm inhibition of MDM2–p53 interaction should probably be done, but we
believe that these first results are really encouraging to demonstrate, inter alia, that the indane core
might be a potential substitute of the oxindole ring, which is so far, the most frequently used in the
inhibition of MDM2–p53 interaction.
Supplementary Materials: The following are available online. Characterization: NMR and HRMS spectra of
5a–5d compounds. Biological assay. Table S1 and Table S2: Control of cell growth of compounds 5a–d against
A549 and SH-SY5Y cells, respectively. Docking studies. Table S3: Docking score of input ligands to MDM2;
Figure S1. Stacked plot of minimum energy docking poses for 5a–d derivatives (A). Detail of exo-(3R,5R)-5a
in green superimposed to p53 in red and grey (B). Figure S2. Snapshot from MD simulation of exo-(3R,5R)-5a
bounded to MDM2 (A). Snapshots from MD at different simulation times of endo-(3R,5S)-5a bounded to complex
MDM2–p53 (B). Figure S3. Snapshots from MD simulation of unbounded p53 and MDM2 at different simulation
times. MDM2 in green, p53: starting structure (yellow), 100 ns (light orange), 200 ns (orange), 300 ns (light red),
400 ns (red), 500 ns (dark red).
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